VXRT - アビラジェン・セラピュ―ティクス (Vaxart Inc.) アビラジェン・セラピュ―ティクス

 VXRTのチャート


 VXRTの企業情報

symbol VXRT
会社名 Vaxart Inc (アビラジェン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バクサルト(Vaxart Inc.)(旧名:Aviragen Therapeutics Inc.)は感染症を治療するための直接作用型抗ウイルス薬の発見・開発に従事する。同社は治療の選択肢が限られるウイルス感染症に対処する臨床開発中の3種類の候補製品を有する。製品は第IIb相の酒精試験で評価されるヒト・ライノウイルス(HRV)感染症の中・重度の喘息患者のための経口治療薬のvapendavir、呼吸器合胞体ウイルス(RSV)感染の治療・予防のための第Ⅱ相開発における経口融合(F)タンパク質阻害剤であるBTA585、ヒトパピローマウイルス6型および11型に起因するコンジロームの第II相開発における局所抗ウィルス治療薬であるBTA074を含む。同社は前臨床RSV非融合阻害剤プログラムを有する。同社は感染症を予防・治療できる小分子化合物の発見と開発に研究と薬剤開発キャパシティを集中する。  アビラジェン・セラピュ―ティクスは米国のバイオ医薬品企業。呼吸関連のウイルス感染に対応する経口・小分子化合物に焦点を当て、インフルエンザの治療向けリレンザ(グラクソスミスクラインより販売)やイナビル(第一三共製薬より販売)を開発したほか、鼻炎の原因であるライノウイルスや、呼吸系発疹ウイルスの治療薬の開発にも従事。本社はジョ―ジア州。   Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
本社所在地 290 Utah Ave. Suite 200 South San Francisco CA 94080 USA
代表者氏名 Wouter Latour ワウターラトゥール
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-550-3500
設立年月日 25263
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 16人
url www.aviragentherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/vxrt
adr_tso
EBITDA EBITDA(百万ドル) -9.26800
終値(lastsale) 4.88
時価総額(marketcap) 34849002.32
時価総額 時価総額(百万ドル) 26.80374
売上高 売上高(百万ドル) 2.95000
企業価値(EV) 企業価値(EV)(百万ドル) 7.39874
当期純利益 当期純利益(百万ドル) -9.05600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Vaxart Inc revenues totaled $2.1M. Net loss applicable to common stockholders totaled to $6.9M. Results are not comparable due to year end change.

 VXRTのテクニカル分析


 VXRTのニュース

   Vaxart: The ‘Show Me’ Story Still Has Potential, Says Analyst  2021/03/12 02:05:50 ADVFN UK
The stock market has been pulled aggressively in both directions in 2021, but the moves are relatively tame compared to the wild ride of…
   Bireme Capital: “Vaxart, Inc. is Exhibiting Classic Pretender Signals”  2021/03/05 15:11:27 Yahoo Finance
Bireme Capital, an investment management firm, published its fourth-quarter 2020 Investor Letter – a copy of which can be downloaded here. A net return of 47.1% was recorded by the fund for the year end 2020, outperforming its S&P500 benchmark that delivered an 18.3% return. You can view the fund’s top 5 holdings to have a […]
   State Street Corporation Reports In 13G Filing An 8.63% In Vaxart  2021/02/11 13:33:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
   Vaxart shares tank following release of preliminary Phase 1 data for oral COVID-19 vaccine tablet – Microbial Biotech News  2021/02/04 16:46:08 Microbial Biotech News
Shares of Vaxart, Inc., (NASDAQ: VXRT) tanked this week following the company’s announcement of preliminary data from the Phase 1 study of its oral tablet COVID-19 vaccine, VXA-CoV2-1
   Vaxart Tanks 58% On Oral COVID-19 Vaccine Early Trial Data; Street Says Buy  2021/02/04 08:13:54 Smarter Analyst
Shares of Vaxart cratered 58% on Feb. 3 after early preliminary trial data showed that its oral COVID-19 vaccine did not produce neutralizing … The post Vaxart Tanks 58% On Oral COVID-19 Vaccine Early Trial Data; Street Says Buy appeared first on Smarter Analyst .
   Vaxart: The ‘Show Me’ Story Still Has Potential, Says Analyst  2021/03/12 02:05:50 ADVFN UK
The stock market has been pulled aggressively in both directions in 2021, but the moves are relatively tame compared to the wild ride of…
   Bireme Capital: “Vaxart, Inc. is Exhibiting Classic Pretender Signals”  2021/03/05 15:11:27 Yahoo Finance
Bireme Capital, an investment management firm, published its fourth-quarter 2020 Investor Letter – a copy of which can be downloaded here. A net return of 47.1% was recorded by the fund for the year end 2020, outperforming its S&P500 benchmark that delivered an 18.3% return. You can view the fund’s top 5 holdings to have a […]
   State Street Corporation Reports In 13G Filing An 8.63% In Vaxart  2021/02/11 13:33:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
   Vaxart shares tank following release of preliminary Phase 1 data for oral COVID-19 vaccine tablet – Microbial Biotech News  2021/02/04 16:46:08 Microbial Biotech News
Shares of Vaxart, Inc., (NASDAQ: VXRT) tanked this week following the company’s announcement of preliminary data from the Phase 1 study of its oral tablet COVID-19 vaccine, VXA-CoV2-1
   Vaxart Tanks 58% On Oral COVID-19 Vaccine Early Trial Data; Street Says Buy  2021/02/04 08:13:54 Smarter Analyst
Shares of Vaxart cratered 58% on Feb. 3 after early preliminary trial data showed that its oral COVID-19 vaccine did not produce neutralizing … The post Vaxart Tanks 58% On Oral COVID-19 Vaccine Early Trial Data; Street Says Buy appeared first on Smarter Analyst .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アビラジェン・セラピュ―ティクス VXRT Vaxart Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)